TriangleHEALTH PROFESSIONAL · SOURCE READING
Loss of heterozygosity of 1p or 16q
Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Wilms Tumor / Treatment of Wilms Tumor / Treatment of stage III Wilms tumor
Loss of heterozygosity of 1p or 16q was shown to influence EFS but not OS in 635 patients with stage III FH Wilms tumor enrolled in the COG AREN0532 or AREN03B2 protocols. When combined, a negative lymph node status (related to histology) and a negative loss of heterozygosity status (related to the primary tumor) was a strong predictor of excellent EFS and OS.[278]
Source links and citations
Patients who had lymph nodes sampled during surgery had improved EFS (4-year EFS rate, 90.3%) relative to patients without lymph nodes sampled (4-year EFS rate, 80.0%; P = .0037). No difference was seen in OS whether lymph nodes were sampled (4-year OS rates, 97.0% for patients with lymph nodes sampled vs. 94.9% for those without lymph nodes sampled; P = .078).
Patients with positive lymph nodes at nephrectomy had worse EFS than those with negative lymph nodes (83.5% vs. 94.2% at 4-years; HR, 2.78; P = .00017). A borderline significant effect was observed for OS (4-year OS rates, 95.1% vs. 98.2%; HR, 2.50; P = .054).
An analysis of patients with stage III Wilms tumor according to lymph node status (positive or negative) and singular loss of heterozygosity of 1p or 16q status (positive for one or negative for both) is shown in Table 7.
Source links and citations
An analysis of patients with stage III Wilms tumor according to lymph node status (positive or negative) and singular loss of heterozygosity of 1p or 16q status (positive for one or negative for both) is shown in Table 7.
| Lymph Node Status | LOH 1p or 16q | 4-Year EFS Ratea | HRb |
|---|---|---|---|
| - = negative; + = positive; EFS = event-free survival; HR = hazard ratio; LOH = loss of heterozygosity. | |||
| aCompared with patients both negative for lymph node and singular LOH, a significant difference in EFS across the groups was observed (log-rank P < .0001). | |||
| bOverall survival did not reach statistical significance between groups. | |||
| - | - | 96.2% | - (n = 212) |
| - | +1p or 16q | 89.5% | 3.04 (n = 72) |
| + | +1p | 73.9% | 6.33 (n = 37) |
| + | +16q | 79.3% | |
| + | - | 86.0% | 3.57 (n = 104) |
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice